Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN)

NCT01334177 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01334177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01334177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN)
Lead sponsor
University of Washington
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2011
Completion date
Not reported
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic squamous neck cancer with occult primary squamous cell carcinoma, recurrent metastatic squamous neck cancer with occult primary, recurrent salivary gland cancer, recurrent squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the nasopharynx, recurrent squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, recurrent verrucous carcinoma of the larynx, recurrent verrucous carcinoma of the oral cavity, salivary gland squamous cell carcinoma, stage iii salivary gland cancer, stage iii squamous cell carcinoma of the hypopharynx, stage iii squamous cell carcinoma of the larynx, stage iii squamous cell carcinoma of the lip and oral cavity, stage iii squamous cell carcinoma of the nasopharynx, stage iii squamous cell carcinoma of the oropharynx, stage iii squamous cell carcinoma of the paranasal sinus and nasal cavity, stage iii verrucous carcinoma of the larynx, stage iii verrucous carcinoma of the oral cavity, stage iv salivary gland cancer, stage iva squamous cell carcinoma of the larynx, stage iva squamous cell carcinoma of the lip and oral cavity, stage iva squamous cell carcinoma of the oropharynx, stage iva squamous cell carcinoma of the paranasal sinus and nasal cavity, stage iva verrucous carcinoma of the larynx, stage iva verrucous carcinoma of the oral cavity, stage ivb squamous cell carcinoma of the larynx, stage ivb squamous cell carcinoma of the lip and oral cavity, stage ivb squamous cell carcinoma of the oropharynx, stage ivb squamous cell carcinoma of the paranasal sinus and nasal cavity, stage ivb verrucous carcinoma of the larynx, stage ivb verrucous carcinoma of the oral cavity, stage ivc squamous cell carcinoma of the larynx, stage ivc squamous cell carcinoma of the lip and oral cavity, stage ivc squamous cell carcinoma of the oropharynx, stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity, stage ivc verrucous carcinoma of the larynx, stage ivc verrucous carcinoma of the oral cavity, tongue cancer